Edgewood Oncology

Edgewood Oncology is a clinical-stage biotechnology company dedicated to delivering the promise of BTX-A51 for patients with hematologic malignancies and hereditary solid tumors. BTX-A51 is a novel small-molecule multi-kinase inhibitor that synergistically targets key regulators of cancer to activate programmed cell death, or apoptosis. BTX-A51 holds potential for use in acute myeloid leukemia and hereditary solid tumors, which are the focus of ongoing clinical programs.